Chairman & CEO · Nuvectis Pharma, Inc. (NVCT)

Ron Bentsur

A named executive officer of Nuvectis Pharma in every fiscal year CompBrief holds from FY2022 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,588,526

Salary $653,987Stock awards $1,395,000Bonus $539,539

FY2024: $1,157,639

1st of 3 named executive officers at Nuvectis Pharma by FY2025 total.

3 named officers on file for Nuvectis Pharma, FY2025

Ron Bentsur’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Nuvectis Pharma’s whole pay program stands against its peers

  • Nuvectis Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NVCT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Ron Bentsur’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Ron Bentsur compensation by year

Nuvectis Pharma Summary Compensation Table · all 4 fiscal years held
In US dollars, as Nuvectis Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024FY2025
Salary$420,360$615,250$634,323$653,987
Bonus$431,250$508,875$523,316$539,539
Stock awards$842,400$1,566,600$0$1,395,000
Option awards$0$0——
Non-equity incentive$0$0——
Pension and deferred compensation$0$0——
All other$0$0——
Total$1,694,010$2,690,725$1,157,639$2,588,526

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Nuvectis Pharma, Inc. DEF 14A filed April 27, 2026, accession 0001104659-26-049476, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Nuvectis Pharma, Inc. filed document, accession 0001104659-26-049476. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.

$1.7M
$2.7M
$1.2M
$2.6M
FY22
FY23
FY24
FY25
SalaryBonusStock awards

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU250,000$1,887,500—
RSU210,000$1,585,500—
RSU120,000$906,000—
RSU96,759$730,530—

Per the Outstanding Equity Awards at Fiscal Year-End table in Nuvectis Pharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2025 proxy (filed April 27, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-30Purchase—12,500$20.003,688,424

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Nuvectis Pharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Ron Bentsur · this pageChairman & CEO$2,588,526
Enrique PoradosuChief Scientific & Business Officer$1,586,241
Shay ShemeshChief Development and Operations Officer$1,586,241

Board service

Nuvectis Pharma board · FY2023–FY2025

How this board is paid

Company policy: Nuvectis Pharma pays directors a $40,000 cash retainer. As stated in Nuvectis Pharma's FY2025 proxy.

The full Nuvectis Pharma compensation record

free company brief

This page is one person within Nuvectis Pharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Nuvectis Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ron Bentsur's compensation dossier · One-time report. No refunds.